Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, randomized, double-blind, active controlled trial comparing Remicade (infliximab) and Remicade plus azathioprine to azathioprine in the treatment of patients with Crohn's disease naive to both immunomodulators and biologic therapy

Next Previous
Trial Profile

Multicenter, randomized, double-blind, active controlled trial comparing Remicade (infliximab) and Remicade plus azathioprine to azathioprine in the treatment of patients with Crohn's disease naive to both immunomodulators and biologic therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infliximab (Primary) ; Azathioprine
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms SONIC
  • Sponsors Centocor; Janssen Biotech

    • Most Recent Events

    • 23 May 2021 Results of a post-hoc analysis from four clinical trials: SONIC, UNITI-1, UNITI-2 and IM-UNITI assessing clinical and endoscopic outcomes of CD patients with non-passable strictures presented at the Digestive Disease Week 2021
    • 13 Oct 2020 Results (n=158) of post-hoc analysis relationship of baseline PRO variables, AP and SF with week 26 clinical remission, PRO2 remission, and corticosteroid-free clinical remission , presented at the 28th United European Gastroenterology Week.
    • 05 Jun 2018 Results of a pooled analysis of ACCENT-I, SONIC, ACT-1, and ACT-2 (n=1205) assessing the association between obesity and response to infliximab, published in the American Journal of Gastroenterology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top